Why do so many people drop out from auto-injection therapy for impotence?
Although intracavernous injection of vasoactive substances has been shown to be a reasonable and reliable method of reversing impotence, studies assessing patient acceptance of this new technology are lacking. By prospectively following patients and willing partners over a 2-year period, this study sought to document patient utilization rates and the reasons why patients decline or discontinue injection therapy. The cumulative dropout rate was 46%, with patients being most at risk for leaving the program after evaluation or during the trial dose phase. Patients decline treatment because they are unable to accept the idea of injecting themselves or because of potential side effects. Patients discontinue treatment because of perceived lack of efficacy. Patient and programatic obstacles to utilization of self-injection therapy are analyzed.
Case Western Reserve University School of Medicine, Cleveland, OH 44106.
S E
SE
Althof
L A
LA
Turner
S B
SB
Levine
C
C
Risen
E
E
Kursh
D
D
Bodner
M
M
Resnick
D007172:Erectile Dysfunction / Q000188:drug therapy*; D008297:Male; D010208:Papaverine / Q000008:administration & dosage / Q000627:therapeutic use*; D010352:Patient Dropouts; D010646:Phentolamine / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D012646:Self Administration
D010208:Papaverine; D010646:Phentolamine